A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06487156 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

404

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Nivolumab + ipilimumab

Sponsor

Bristol-Myers Squibb